Rule 8 - PPL Therapeutics PLC
13 Noviembre 2003 - 7:43AM
UK Regulatory
RNS Number:0389S
TD Waterhouse Investor Services
13 November 2003
Date of Disclosure 13 NOVEMBER 2003
DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3
OF THE CITY CODE ON TAKEOVERS AND MERGERS
Date of dealing 11TH NOVEMBER 2003
Dealing in PPL THERAPEUTICS PLC (name of company)
1) Class of securities (eg ordinary shares) ORDINARY SHARES
2) Amount bought Amount sold Price per unit
200,000 0.046
3) Resultant total of the same class owned or controlled
(and percentage of class) 1,500,000 (1.3%)
4) Party making disclosure TD WATERHOUSE INVESTOR SERVICES (EUROPE) LTD
5) EITHER (a) Name of purchaser/vendor (Note 1) INNOVATION DEVELOPMENT LTD
OR (b) if dealing for discretionary client(s), name of fund
management organisation
6) Reason for disclosure (Note 2)
(a) associate of (i) offeror (Note 3) NO
(ii) offeree company NO
Specify which category or categories of associate (1-8 overleaf)
If category (8), explain
(b) Rule 8.3 (ie disclosure because of ownership or control of 1%
or more of the class of relevant securities dealt in) YES
Signed, for and on behalf of the party named in (4) above N/A
(Also print name of signatory) NEIL J MUTTOCK
Telephone and extension number 020 7704 9997
Note 1. Specify owner, not nominee or vehicle company. If relevant, also
identify controller of owner, eg where an owner normally acts on
instructions of a controller
Note 2. Disclosure might be made for more than one reason; if so, state all
reasons.
Note 3. Specify which offeror if there is more than one.
Note 4. When an arrangement exists with any offeror, with the offeree company
or which an associate of any offeror or of the offeree company
in relation to relevant securities, details of such arrangement must
be disclosed, as required by Note 6 on Rule 8
Note 5. It may be necessary, particularly when disclosing derivative
transactions, to append a sheet to this disclosure form so that
relevant information can be given.
Note 6. In the case of an average price bargain, each underlying trade
should be disclosed.
For full details of disclosure requirements, see Rule 8 of the Code. If in
doubt, contact the Panel on Takeovers and Mergers, Tel No: 020 7382 9026
This information is provided by RNS
The company news service from the London Stock Exchange
END
DCCEAAFDFLDDFFE